10-K: Altria Reports 2025 Earnings Amid E-Vapor Impairments

Altria Group, Inc. reported a significant decline in reported net earnings for 2025 due to substantial e-vapor segment impairments, despite growth in adjusted diluted EPS and progress in its smoke-free portfolio.

Summary

• Reported net earnings for the year ended December 31, 2025, were $6,947 million, a decrease of 38.3% from $11,264 million in 2024.
• Reported diluted earnings per share (EPS) for 2025 was $4.12, down 37.0% from $6.54 in 2024.
• Adjusted net earnings increased by 2.4% to $9,148 million in 2025 from $8,936 million in 2024.
• Adjusted diluted EPS grew by 4.4% to $5.42 in 2025 from $5.19 in 2024.
• Smokeable products segment net revenues decreased by $719 million (3.4%) to $20,485 million, primarily due to a 10.0% decline in cigarette shipment volume to 61.8 billion units, partially offset by higher pricing.
• Oral tobacco products segment net revenues increased by $26 million (0.9%) to $2,802 million, driven by higher pricing, but partially offset by a 5.5% decrease in shipment volume to 732.4 million units and a mix shift.
• The e-vapor products segment reported an operating companies income (OCI) loss of $2,297 million in 2025, significantly wider than the $171 million loss in 2024, primarily due to non-cash impairment charges.
• Total non-cash goodwill impairment for the e-vapor reporting unit in 2025 was $1,158 million, and definite-lived intangible assets impairment was $970 million.
• The U.S. nicotine pouch category grew to 56.9% of the U.S. oral tobacco category in Q4 2025, an increase of 10.4 share points from Q4 2024.
• Altria's on! nicotine pouch brand's share of the nicotine pouch category was 15.4%, a decrease of 3.4 share points.
• The domestic cigarette industry volume declined by an estimated 6.5% in Q4 2025 compared to Q4 2024, a moderation from the 8% decline in Q3 2025.
• Illicit flavored disposable e-vapor products are estimated to represent approximately 70% of the e-vapor category.
• The Board authorized a $1.0 billion share repurchase program in January 2025, expanded to $2.0 billion in October 2025, with $1.0 billion remaining at December 31, 2025.
• The quarterly dividend rate was increased by 3.9% to $1.06 per share in Q3 2025, targeting mid-single digits dividend per share growth annually through 2028.
• The debt-to-Consolidated EBITDA ratio was 2.0x at December 31, 2025, meeting the target of approximately 2.0x.
• The multi-phase Optimize & Accelerate initiative is expected to deliver cumulative savings of at least $600 million by the end of 2029, with estimated pre-tax charges updated to approximately $175 million.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed filing with significant headwinds. The substantial non-cash impairments in the e-vapor segment and the ITC ban on NJOY ACE overshadow the adjusted earnings growth and strategic efforts in smoke-free products, indicating ongoing challenges in a rapidly evolving and competitive market.

Positives

• Adjusted net earnings increased by 2.4% and adjusted diluted EPS increased by 4.4% year-over-year.
• Oral tobacco products segment net revenues grew by 0.9% and adjusted OCI increased by 1.3%.
• FDA Marketing Granted Orders (MGOs) were received for on! PLUS oral nicotine pouches in tobacco, mint, and wintergreen flavors (6mg and 9mg nicotine levels) in December 2025.
• Cigar shipment volume increased by 1.8% in 2025.
• Marlboro's retail share of the premium segment increased by 0.1 share point to 59.4%.
• The domestic cigarette industry volume decline rate moderated to an estimated 6.5% in Q4 2025, an improvement from 8% in Q3 2025.
• The company achieved its target debt-to-Consolidated EBITDA ratio of 2.0x.
• The Board approved a 3.9% increase in the quarterly dividend rate, aligning with the progressive dividend goal targeting mid-single digits growth annually through 2028.
• The share repurchase program was expanded to $2.0 billion, demonstrating commitment to shareholder returns.
• The Optimize & Accelerate initiative is projected to yield at least $600 million in cumulative savings by the end of 2029.
• The Occupational Safety and Health Administration recordable injury rate for 2025 was 1.7%, remaining below the industry benchmark.
• The company's cybersecurity program consistently receives assessments indicating it is ahead of its peer group.

Negatives

• Reported net earnings decreased by 38.3% and reported diluted EPS decreased by 37.0% in 2025, primarily due to the absence of the IQOS System commercialization rights gain from 2024 and significant e-vapor impairments.
• The e-vapor products segment incurred substantial non-cash impairment charges totaling $2,128 million in 2025, leading to a significant OCI loss of $2,297 million.
• NJOY ACE is subject to ITC exclusion and cease-and-desist orders, prohibiting its importation and sale in the U.S., negatively impacting the e-vapor business.
• Illicit flavored disposable e-vapor products are estimated to comprise approximately 70% of the e-vapor category, hindering the growth of FDA-authorized products.
• Smokeable products segment net revenues decreased by 3.4% and domestic cigarette shipment volume declined by 10.0%.
• Oral tobacco products segment shipment volume decreased by 5.5%, and on! nicotine pouch share of the nicotine pouch category declined by 3.4 share points.
• Discretionary income pressures on adult nicotine consumers, persistent inflation, and tariffs contributed to increased discount brand share and negatively impacted premium brand sales.
• The estimated pre-tax charges for the Optimize & Accelerate initiative were increased to approximately $175 million from $125 million.
• An unfavorable ruling by the U.S. District Court for the Eastern District of Virginia regarding downward attribution rules for the 2017 tax year has potential implications for 2018-2025 tax years.
• PM USA owes $31 million to the State of Texas and $10 million to the State of Minnesota, plus interest, due to profit adjustment payment disputes.

Risks

• Unsuccessful anticipation and response to changes in adult nicotine consumer purchase behavior and preferences, including due to difficult economic conditions, inflation, and down-trading to lower-priced products.
• Significant competition, including from the growth of innovative nicotine products (legal and illicit e-vapor, oral nicotine pouches), impacting profitability, market share, and shipment volume.
• Failure to compete effectively in innovative nicotine product categories or to obtain or maintain regulatory authorization for marketing or sale of these products.
• Inability to successfully counter the effects of illicit trade in nicotine products, particularly illicit flavored disposable e-vapor products, leading to adverse impacts on sales, brand perception, and potential government actions.
• Failure to complete or manage strategic transactions, including acquisitions, dispositions, joint ventures, and investments, or to realize their anticipated benefits (e.g., NJOY Transaction, Cronos investment).
• Significant changes in price, availability, or quality of tobacco, other raw materials, or component parts due to macroeconomic conditions, adverse weather, government restrictions, trade disruptions, inflation, geopolitical instability, and single-use plastic bans.
• Reliance on a few significant manufacturing facilities and a small number of key suppliers, distributors, and distribution chain service providers, with potential for extended disruptions.
• Requirement to write down goodwill and other intangible assets due to impairment, as demonstrated by the e-vapor reporting unit and Skoal trademark impairments.
• Increased risks related to business continuity, internal control over financial reporting, and audit procedures due to the Optimize & Accelerate initiative, including potential loss of continuity, talent management issues, and outsourcing risks.
• Product recalls due to quality standards failure, contamination, misbranding, or tampering, which could have negative economic consequences and reputational harm.
• Various risks related to health epidemics and pandemics, and governmental measures to address them.
• Inability to attract and retain a highly skilled workforce due to the decreasing social acceptance of tobacco usage and tobacco control actions.
• Unfavorable outcomes with respect to litigation proceedings or governmental investigations (e.g., product liability, antitrust, patent infringement, RICO), potentially leading to significant non-monetary remedies or substantial damages.
• Significant federal, state, and local governmental actions, including FDA regulatory actions and inaction (e.g., product standards, flavor bans, lengthy PMTA review periods, inadequate enforcement against illicit products).
• Substantial taxation on nicotine products, and any increases in taxes could adversely impact sales volumes and shift consumers to lower-priced or illicit products.
• International business operations subject to various U.S. and foreign laws and regulations, with potential for reputational harm, legal challenges, and significant penalties for violations.
• Challenges to tax positions, increases in income tax rates, or other changes to federal or state tax laws, including those related to duty drawback and downward attribution rules.
• Legal and regulatory requirements related to climate change and other environmental sustainability matters, potentially increasing compliance and manufacturing costs.
• Disruption and uncertainty in the credit and capital markets, which could materially adversely affect liquidity, borrowing costs, and access to financing.
• A downgrade or potential downgrade of credit ratings, which could adversely impact borrowing costs and access to credit and capital markets.
• Impact on reputation, ability to attract investors, and market value of stock due to corporate responsibility matters and stakeholder responses.
• Failure of information systems, cyber-attacks, or security breaches, including those involving third-party service providers and artificial intelligence technologies.
• Failure to comply with personal data protection, privacy, artificial intelligence, and information security laws.
• The expected benefits of investments in Anheuser-Busch InBev SA/NV (ABI) and Cronos Group Inc. (Cronos) may not materialize as anticipated, due to factors such as foreign currency exchange rates, business results, share price fluctuations, and impairment losses.

Future Outlook

Altria targets a mid-single digits adjusted diluted EPS compounded annual growth rate through 2028 from a $4.87 base in 2022, alongside a progressive dividend goal targeting mid-single digits dividend per share growth annually through 2028. The company aims to maintain a debt-to-Consolidated EBITDA ratio of approximately 2.0x and a total adjusted OCI margin of at least 60% through 2028. Smoke-free goals are being reassessed due to market disruption from illicit e-vapor products, with updated goals expected once there is more clarity. The Optimize & Accelerate initiative is expected to deliver cumulative savings of at least $600 million by the end of 2029, with these savings reinvested into the business. Capital expenditures for 2026 are projected to be between $300 million and $375 million, funded by operating cash flows. The company does not anticipate a material impact from tariffs on costs in 2026 and expects future product liability defense costs for its smokeable products segment to be consistent with 2025 levels.

Management Comments

• "We are Moving Beyond Smoking TM, by responsibly transitioning adult smokers to a smoke-free future, competing vigorously for existing smoke-free adult nicotine consumers and exploring new growth opportunities beyond the United States and beyond nicotine."
• "We remain steadfast in our commitment to our Vision and to building a portfolio of FDA-authorized smoke-free products for adult smokers and adult nicotine consumers currently using smoke-free products."
• "We continue to plan to reinvest these savings [from Optimize & Accelerate initiative] in our businesses in support of our Vision and 2028 Goals."
• "We have increased engagement with the FDA and other government agencies to encourage enforcement action against these illicit products, but such enforcement has been inadequate to date."
• "We do not believe the trends and developments discussed above have materially impacted our ability to achieve our Vision."
• "We believe that the public should be guided by the messages of the U.S. Surgeon General and public health authorities worldwide in making decisions concerning the use of tobacco products, including e-vapor products."
• "We believe, and have been so advised by counsel handling the respective cases, that we have valid defenses to the litigation pending against us, as well as valid bases for appeal of adverse verdicts. We have defended, and will continue to defend, vigorously against litigation challenges. However, we may enter into settlement discussions in particular cases if we believe it is in our best interests to do so."
• "Compliance with environmental laws and regulations, including the payment of any remediation costs or damages and related expenditures, has not had, and is not expected to have, a material adverse effect on our business, results of operations, capital expenditures, financial position or cash flows."

Industry Context

StockSavvy.ai notes that Altria operates in a challenging and evolving industry, marked by declining traditional cigarette volumes and a strategic shift towards innovative smoke-free products. The significant growth of illicit flavored disposable e-vapor products, estimated to comprise 70% of the e-vapor category, creates a complex competitive landscape and regulatory enforcement challenge for companies like Altria that are investing in FDA-authorized alternatives. The company's strategic focus on "Moving Beyond Smoking" aligns with broader public health trends and consumer preferences for reduced-risk products, but faces headwinds from both regulatory uncertainty and the unregulated market. The continued growth of the nicotine pouch category, where Altria's on! brand competes, indicates a key area of industry transition, although Altria's share in this specific segment has seen a slight decline.

Comparison to Industry Standards

• The Occupational Safety and Health Administration recordable injury rate for 2025 was 1.7%, which is below the benchmark for companies in the U.S. Beverage and Tobacco Product Manufacturing industry classification.
• Altria's cybersecurity program consistently receives assessments indicating it is ahead of the cybersecurity programs of its peer group.

Management Changes

Corporate Governance

Legal Proceedings

• In February 2026, an arbitration panel found that Missouri was not diligent in the enforcement of its escrow statutes in 2005, related to Non-Participating Manufacturer (NPM) Adjustment Disputes.
• PM USA expects to receive $28 million in April 2026 from the Massachusetts NPM Adjustment settlement through 2011.
• PM USA will receive a $53 million credit against its 2026 MSA payment from the Washington NPM Adjustment settlement through 2015.
• PM USA appealed a U.S. District Court for the Eastern District of Texas ruling that found PM USA owes $31 million plus interest to the State of Texas for profit adjustment payments.
• PM USA intends to appeal a Minnesota state court ruling that found PM USA owes $10 million plus interest to the State of Minnesota for profit adjustment payments.
• Canadian tobacco product-related claims and litigation against Altria and PM USA will be dismissed following the implementation of a plan for three Canadian tobacco manufacturers in August 2025.
• In February 2026, the U.S. District Court for the Northern District of California certified three classes of plaintiffs (direct purchasers, indirect purchasers, indirect resellers) in the In Re JUUL Labs, Inc. Antitrust Litigation, with trial set for May 2026.
• The ITC issued an exclusion order and cease-and-desist orders prohibiting the importation and sale of NJOY ACE in the U.S., effective March 31, 2025; Altria has appealed this decision.
• JUUL filed a patent infringement lawsuit against Altria and its affiliates in the U.S. District Court for the District of Arizona and a related ITC action in August 2025, based on the sale of NJOY Daily.
• NJOY filed a patent infringement complaint against JUUL in the U.S. District Court for the District of Delaware and a related ITC action in September 2025, based on the sale of certain JUUL e-vapor products.
• The U.S. Court of Appeals for the Federal Circuit affirmed a $95 million damages award and a 5.25% royalty on future sales for ALCS in its patent infringement lawsuit against R.J. Reynolds in December 2024; the U.S. Supreme Court denied R.J. Reynolds' petition for review in October 2025.
• Altria settled federal and state shareholder derivative lawsuits related to its former investment in JUUL, agreeing to provide $100 million over five years for underage tobacco prevention and cessation programs.
• The U.S. District Court for the Eastern District of Virginia ruled in favor of the IRS, denying Altria's refund claim for the 2017 tax year based on the removal of downward attribution rules, with Altria intending to vigorously contest the ruling.

Related Party Transactions

• Philip Morris USA Inc. (PM USA), a 100% owned subsidiary, fully and unconditionally guarantees Altria Group, Inc.'s (Parent) obligations under its outstanding debt securities, borrowings under its Credit Agreement, and amounts outstanding under its commercial paper program.
• Altria Group, Inc. guarantees the financial obligations of Altria Client Services LLC (ALCS) under a supplier financing program.
• Under a distribution agreement with Philip Morris International Inc. (PMI), liabilities concerning tobacco products are allocated based on the manufacturer, with PMI indemnifying Altria/PM USA for PMI-manufactured products and PM USA indemnifying PMI for PM USA-manufactured products (excluding contract manufactured for PMI).

Stakeholder Impact

• Shareholders: Impacted by a significant decrease in reported net earnings and EPS, but also by growth in adjusted EPS and a progressive dividend policy. The expanded share repurchase program and management changes are also relevant.
• Employees: The Optimize & Accelerate initiative involves organizational changes, including centralizing work and outsourcing, which could affect roles and responsibilities. The company emphasizes attracting, developing, and retaining talent, and promoting a safe workplace.
• Customers: Facing macroeconomic pressures (inflation, tariffs) leading to shifts in purchasing behavior towards discount brands and across product categories. Product availability is impacted by regulatory actions, such as the NJOY ACE import ban.
• Suppliers: Challenging economic conditions may lead to financial or operational difficulties for suppliers. The company manages supply chain human capital risks through due diligence and adherence to labor management and human rights standards.
• Creditors: The company's credit ratings and debt-to-EBITDA ratio are key factors for creditors, with PM USA guaranteeing Altria's debt obligations. The extension of the revolving credit agreement provides continued liquidity access.

Next Steps

• Commercialize additional on! and NJOY products.
• Continue to reinvest savings from the Optimize & Accelerate initiative in businesses.
• Continue to monitor the impact of increased inflation on the macroeconomic environment and businesses.
• Continue to monitor other effects of tariffs on businesses.
• Continue to engage with the FDA and other government agencies to encourage enforcement action against illicit e-vapor products.
• Continue to evaluate the potential impacts of evolving trends and new developments on businesses, investments, and Vision.
• Complete the majority of the remaining charges for the Optimize & Accelerate initiative by the end of 2027.
• Make employer contributions in 2026 to pension plans of up to approximately $60 million and to postretirement plans of up to approximately $100 million.
• Fund capital expenditures for 2026, estimated to be in the range of $300 million to $375 million, from operating cash flows.
• File the definitive proxy statement for the annual meeting of shareholders on or about April 2, 2026.
• Trial for the remaining claims in the In Re JUUL Labs, Inc. Antitrust Litigation is set to commence in May 2026.
• An evidentiary hearing in the R.J. Reynolds patent litigation is estimated for February or March 2026.
• Expect an initial determination from the ALJ in JUUL's patent infringement action against NJOY Daily in September 2026, with the ITC's final determination expected in January 2027.
• Expect an initial determination from the ALJ in NJOY's patent infringement action against JUUL in September 2026, with the ITC's final determination expected in April 2027.
• Vigorously contest the U.S. District Court for the Eastern District of Virginia ruling on downward attribution rules by pursuing all available appellate remedies.

Key Dates

Recommendation

The filing presents a complex picture. While Altria achieved adjusted diluted EPS growth and maintained its dividend growth target, the substantial non-cash impairments in the e-vapor segment and the ITC ban on NJOY ACE highlight significant challenges in its "Moving Beyond Smoking" strategy. The core smokeable products business continues to face volume declines, albeit with some moderation in Q4 2025. The company's strong cash flow generation and commitment to shareholder returns (dividends, share repurchases) provide a floor, but the regulatory and competitive environment for innovative products remains highly uncertain and costly. Investors should hold, awaiting clearer signs of effective enforcement against illicit e-vapor products and more consistent growth from Altria's smoke-free portfolio to justify a more bullish stance.

Keywords

Altria, tobacco, cigarettes, smoke-free products, e-vapor, oral nicotine pouches, NJOY, Marlboro, Copenhagen, Skoal, financial results, SEC filing, 10-K, annual report, impairment, litigation, FDA regulation, excise taxes, dividends, share repurchase, corporate governance, risk factors, ABI, Cronos